Songping Zhao

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 5

Top Topics

Molecular Dynamics Simulations

Tyrosine Kinase

Oxidative Stress

Top Venues

Proceedings of the National Academy of Sciences of the United States of America

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Heike Schonherr, Pelin Ayaz, Alexander M Taylor, Jessica B Casaletto, B Barry Toure, Demetri T Moustakas, Brandi M Hudson, Roberto Valverde, Songping Zhao, Patrick J O'Hearn, Lindsey Foster, Dina A Sharon, Sam Garfinkle, Fabrizio Giordanetto, André Lescarbeau, Ravi Kurukulasuriya, Nastaran Gerami-Moayed, Dejan Maglic, Kamil Bruderek, Gaauri Naik, Hakan Gunaydin, Mary M Mader, Alessandro A Boezio, Thomas H McLean, Rongfeng Chen, Yanxia Wang, David E Shaw, James Watters, Donald A Bergstrom
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2. Proceedings of the National Academy of Sciences of the United States of America 121 (6) (2024)
Heike Schonherr, Pelin Ayaz, Alexander M Taylor, Jessica B Casaletto, B Barry Toure, Demetri T Moustakas, Brandi M Hudson, Roberto Valverde, Songping Zhao, Patrick J O'Hearn, Lindsey Foster, Dina A Sharon, Sam Garfinkle, Fabrizio Giordanetto, André Lescarbeau, Ravi Kurukulasuriya, Nastaran Gerami-Moayed, Dejan Maglic, Kamil Bruderek, Gaauri Naik, Hakan Gunaydin, Mary M Mader, Alessandro A Boezio, Thomas H McLean, Rongfeng Chen, Yanxia Wang, David E Shaw, James Watters, Donald A Bergstrom
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2. Proceedings of the National Academy of Sciences of the United States of America 121 (6) (2024)
Heike Schonherr, Pelin Ayaz, Alexander M Taylor, Jessica B Casaletto, B Barry Toure, Demetri T Moustakas, Brandi M Hudson, Roberto Valverde, Songping Zhao, Patrick J O'Hearn, Lindsey Foster, Dina A Sharon, Sam Garfinkle, Fabrizio Giordanetto, André Lescarbeau, Ravi Kurukulasuriya, Nastaran Gerami-Moayed, Dejan Maglic, Kamil Bruderek, Gaauri Naik, Hakan Gunaydin, Mary M Mader, Alessandro A Boezio, Thomas H McLean, Rongfeng Chen, Yanxia Wang, David E Shaw, James Watters, Donald A Bergstrom
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2. Proceedings of the National Academy of Sciences of the United States of America 121 (6) (2024)
Heike Schonherr, Pelin Ayaz, Alexander M Taylor, Jessica B Casaletto, B Barry Toure, Demetri T Moustakas, Brandi M Hudson, Roberto Valverde, Songping Zhao, Patrick J O'Hearn, Lindsey Foster, Dina A Sharon, Sam Garfinkle, Fabrizio Giordanetto, André Lescarbeau, Ravi Kurukulasuriya, Nastaran Gerami-Moayed, Dejan Maglic, Kamil Bruderek, Gaauri Naik, Hakan Gunaydin, Mary M Mader, Alessandro A Boezio, Thomas H McLean, Rongfeng Chen, Yanxia Wang, David E Shaw, James Watters, Donald A Bergstrom
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2. Proceedings of the National Academy of Sciences of the United States of America 121 (6) (2024)
Vivek Subbiah, Vaibhav Sahai, Dejan Maglic, Kamil Bruderek, B Barry Toure, Songping Zhao, Roberto Valverde, Patrick J O'Hearn, Demetri T Moustakas, Heike Schonherr, Nastaran Gerami-Moayed, Alexander M Taylor, Brandi M Hudson, Damian J Houde, Debjani Pal, Lindsey Foster, Hakan Gunaydin, Pelin Ayaz, Dina A Sharon, Lipika Goyal, Alison M Schram, Suneel D Kamath, Cori Ann Sherwin, Oleg Schmidt-Kittler, Kai Yu Jen, Fabien Ricard, Beni B Wolf, David E Shaw, Donald A Bergstrom, James Watters, Jessica B Casaletto
RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations. Cancer discovery (2023)